Top

Annals of Hematology

Published in:

01-03-2019 | Lymphoma | Letter to the Editor

Blastic plasmacytoid dendritic cell neoplasm with response to pralatrexate

Authors: Shuku Sato, Eri Tanaka, Yotaro Tamai

Published in: Annals of Hematology | Issue 3/2019

Excerpt

Dear Editor, …

Petrella T, Facchetti F (2010) Tumoral aspects of plasmacytoid dendritic cells: what do we know in 2009. Autoimmunity 43(3):210–214CrossRefPubMed

Bueno C, Almeida J, Lucio P, Marco J, Garcia R, de Pablos JM, Parreira A, Ramos F, Ruiz-Cabello F, Suarez-Vilela D, San Miguel JF, Orfao A (2004) Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica 89(1):58–69PubMed

Julia F, Petrella T, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, Dereure O, Wetterwald M, d'Incan M, Grange F, Cornillon J, Tertian G, Maubec E, Saiag P, Barete S, Templier I, Aubin F, Dalle S (2013) Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol 169(3):579–586CrossRefPubMed

Feuillard J, Jacob MC, Valensi F, Maynadie M, Gressin R, Chaperot L, Arnoulet C, Brignole-Baudouin F, Drenou B, Duchayne E, Falkenrodt A, Garand R, Homolle E, Husson B, Kuhlein E, Le Calvez G, Sainty D, Sotto MF, Trimoreau F, Bene MC (2002) Clinical and biologic features of CD4 CD56 malignancies. Blood 99(5):1556–1563CrossRefPubMed

Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, Iriondo Atieza A, Arcese W, Beelen DW, Cornilissen JJ, Kroger N, Milone G, Rossi G, Jardin F, Peter C, Rocha V, Sureda A, Mohty M, Dreger P (2013) European Group for blood and marrow transplantation lymphoma, pediatric diseases, and acute leukemia working parties. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 121(3):440–446CrossRefPubMed

Aoki T, Suzuki R, Kuwatsuka Y, Kako S, Fujimoto K, Taguchi J, Kondo T, Ohata K, Ito T, Kamoda Y, Fukuda T, Ichinohe T, Takeuchi K, Izutsu K, Suzumiya J (2015) Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood 125(23):3559–3562CrossRefPubMed

Sugimoto KJ, Shimada A, Yamaguchi N, Imai H, Wakabayashi M, Sekiguchi Y, Izumi H, Ota Y, Komatsu N, Noguchi M (2013) Sustained complete remission of a limited-stage blastic plasmacytoid dendritic cell neoplasm followed by a simultaneous combination of low-dose DeVIC therapy and radiation therapy: a case report and review of the literature. Int J Clin Exp Pathol 6(11):2603–2608PubMedPubMedCentral

Fontaine J, Thomas L, Balame B, Ronger-Savle S, Traulle C, Petrella T, Dalle S (2009) Haematodermic CD4+CD56+ neoplasm: complete remission after methotrexate-asparaginase treatment. Clin Exp Dermatol 34(5):43–45CrossRef

Yamaguchi M, Kita K, Miwa H, Nishii K, Oda K, Ohno T, Shirakawa S, Fukumoto M (1995) Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 76(11):2351–2356CrossRefPubMed

10.

Angelot-Delettre F, Roggy A, Frankel AE, Lamarthee B, Seilles E, Biichle S, Royer B, Deconinck E, Rowinsky EK, Brooks C, Bardet V, Benet B, Bennani H, Benseddik Z, Debliquis A, Lusina D, Roussel M, Solly F, Ticchioni M, Saas P, Garnache-Ottou F (2015) In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent. Haematologica 100(2):223–230CrossRefPubMedPubMedCentral

11.

Serova M, Bieche I, Sablin M-P, Oronk GJ, Vidaud M, Cvitkovic E, Faivre S, Raymond E (2011) Single agent and combination studies of pralatrexate and molecular correlates of sensitivity. Br J Cancer 104(2):272–280CrossRefPubMed

12.

Justin J. Leitenberger BS, Cindy NB, , Kristel DP, Marbara P, Perter ML, Dan J, Madeleine D (2008) CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate. J Am Acad Dermatol 58(3):480–484CrossRef

13.

Arranto C, Tzankov A, Halter J (2017) Blastic plasmacytoid dendritic cell neoplasm with transient response to pralatrexate. Ann Hematol 96(4):681–682CrossRefPubMed

Title: Blastic plasmacytoid dendritic cell neoplasm with response to pralatrexate
Authors: Shuku Sato
Eri Tanaka
Yotaro Tamai
Publication date: 01-03-2019
Publisher: Springer Berlin Heidelberg
Keywords: Lymphoma
Blastic Plasmacytoid Dendritic Cell Neoplasm
Cytostatic Therapy
Published in: Annals of Hematology / Issue 3/2019
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-019-03611-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Blastic plasmacytoid dendritic cell neoplasm with response to pralatrexate

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2019

Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI

Clinical and genetic characterization of de novo double-hit B cell precursor leukemia/lymphoma

Prominent regression of corneal crystalline deposits in multiple myeloma after treatment with proteasome inhibitor

The impact of chronic myeloid leukemia on employment: the French prospective study

Clinical characteristics and the long-term outcome of patients with atypical POEMS syndrome variant with undetectable monoclonal gammopathy

Structural modeling of a novel TERC variant in a patient with aplastic anemia and short telomeres

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page